Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LabCorp widens immunoassay range

This article was originally published in Clinica

Executive Summary

LabCorp, the Burlington, North Carolina-based diagnostics developer and lab testing service provider, is to offer what is said to be a "more sensitive" screening technology for assessing the risk of Down syndrome in pregnant women, following a licensing agreement with the test's developer, Intema. LabCorp said the deal makes it the first US national clinical laboratory to offer the UK company's integrated and sequential screening technology for Down syndrome, which combines test results from the first and second trimester to detect more accurately Down syndrome in the foetus.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048425

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel